Navigation Links
BD Announces Results for First Fiscal Quarter
Date:1/28/2009

FRANKLIN LAKES, N.J., Jan. 28 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of $1.734 billion for the first fiscal quarter ended December 31, 2008, representing an increase of 1.6 percent from the prior year period. This quarter's growth rate reflects the unfavorable impact from foreign currency translation, which overall is estimated to account for nearly 3 percentage points.

"BD is off to a solid start to fiscal 2009. In particular, we continue to see strength in our Biosciences and Diagnostics segments and strong sales of insulin delivery products," said Edward J. Ludwig, Chairman and Chief Executive Officer. "In addition, our strong earnings per share growth has given us the confidence to raise guidance for fiscal 2009."

Diluted earnings per share from continuing operations of $1.26 for the first fiscal quarter of 2009 increased by 18 percent from diluted earnings per share from continuing operations of $1.07 for the first fiscal quarter of 2008. These earnings reflect underlying performance as well as the overall impact of foreign exchange fluctuations, including foreign exchange hedging gains.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $891 million, representing a decrease of 2 percent from the prior year period after taking into account an estimated 4 percentage points of unfavorable impact from foreign currency translation. Strong sales of insulin delivery products were more than offset by a decline in the sales of Medical Surgical Systems products and the expected decline in sales of prefillable devices in the U.S.

In the BD Diagnostics segment, worldwide revenues for the quarter were $540 million, representing an increase of 3 percent from the prior year period after taking into account an estimated 3 percentage points of unfavorable impact from foreign currency translation. Sales of safety-engineered devices, cancer diagnostics products and infectious disease testing systems contributed to revenue growth.

In the BD Biosciences segment, worldwide revenues for the quarter were $303 million, representing an increase of 11 percent from the prior year period after taking into account an estimated 1 percentage point of favorable impact from foreign currency translation. Demand for clinical and research instruments were the primary growth drivers.

Geographic Results

First quarter revenues in the U.S. were $809 million, representing an increase of 2 percent from the prior year period. Revenues outside the U.S. were $925 million, representing an increase of 1 percent from the prior year period, and reflect an estimated 5 percentage points of unfavorable impact from foreign currency translation.

Fiscal 2009 Outlook for Full Year

The Company estimates that diluted earnings per share from continuing operations for the full fiscal year 2009 will increase approximately 9 to 11 percent over diluted earnings per share from continuing operations of $4.46 for the fiscal year 2008.

Conference Call Information

A conference call regarding BD's first quarter results and its expectations for the full fiscal year will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Wednesday, January 28, 2009. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on February 4, 2009, access code 81318661.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2009 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates, particularly in light of increased volatility in currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation, including changes in government pricing and reimbursement policies or other cost containment reforms; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in thousands, except per share data)

                                          Three Months Ended December 31,
                                           2008        2007        % Change
                                        ----------  ----------     --------

    REVENUES                            $1,733,505  $1,705,767        1.6

    Cost of products sold                  804,298     829,846       (3.1)
    Selling and administrative             409,942     421,718       (2.8)
    Research and development                97,457      91,527        6.5
                                        ----------  ----------       ----
    TOTAL OPERATING COSTS
     AND EXPENSES                        1,311,697   1,343,091       (2.3)
                                        ----------  ----------       ----

    OPERATING INCOME                       421,808     362,676       16.3

    Interest income                          1,651      13,528      (87.8)
    Interest expense                        (7,824)    (10,339)     (24.3)
    Other income, net                        9,411         707         NM
                                        ----------  ----------       ----

    INCOME FROM CONTINUING OPERATIONS
     BEFORE INCOME TAXES                   425,046     366,572       16.0

    Income tax provision                   112,978      95,676       18.1
                                        ----------  ----------       ----

    INCOME FROM CONTINUING OPERATIONS      312,068     270,896       15.2

    INCOME FROM DISCONTINUED OPERATIONS
     NET OF INCOME TAX PROVISION OF
     $8 AND $386, RESPECTIVELY                  14         652         NM
                                        ----------  ----------       ----

    NET INCOME                          $  312,082  $  271,548       14.9
                                        ----------  ----------       ----

    EARNINGS PER SHARE

    Basic:
    Income from continuing operations   $     1.29  $     1.11       16.2
    Income from discontinued operations $        -  $        -          -
    Net income                          $     1.29  $     1.11       16.2

    Diluted:
    Income from continuing operations   $     1.26  $     1.07       17.8
    Income from discontinued operations $        -  $        -          -
    Net income                          $     1.26  $     1.07       17.8


    AVERAGE SHARES OUTSTANDING

         Basic                             242,397     244,292
         Diluted                           248,311     253,116
                                        ----------  ----------

    NM - Not Meaningful



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY SEGMENT AND GEOGRAPHIC AREA
    (Unaudited; Amounts in thousands)

                          Three Months Ended December 31,
                           2008        2007      % Change
                        ----------  ----------   --------

    BD MEDICAL
    ----------
       United States    $  407,508  $  407,491        -
       International       483,268     501,793     (3.7)
                        ----------  ----------     ----
    TOTAL               $  890,776  $  909,284     (2.0)
                        ----------  ----------     ----

    BD DIAGNOSTICS
    --------------
       United States    $  287,568  $  279,488      2.9
       International       252,623     243,263      3.8
                        ----------  ----------     ----
    TOTAL               $  540,191  $  522,751      3.3
                        ----------  ----------     ----

    BD BIOSCIENCES
    --------------
       United States    $  113,751  $  103,071     10.4
       International       188,787     170,661     10.6
                        ----------  ----------     ----
    TOTAL               $  302,538  $  273,732     10.5
                        ----------  ----------     ----

    TOTAL REVENUES
    --------------
       United States    $  808,827  $  790,050      2.4
       International       924,678     915,717      1.0
                        ----------  ----------     ----
    TOTAL               $1,733,505  $1,705,767      1.6
                        ----------  ----------     ----



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended December 31,
    (Unaudited; Amounts in thousands)

                                        United States
                                 -----------------------------
                                   2008      2007     % Change
                                 --------  --------   --------

    BD MEDICAL
    ----------
       Medical Surgical Systems  $256,255  $252,745      1.4
       Diabetes Care              101,812    98,526      3.3
       Pharmaceutical Systems      42,652    49,978    (14.7)
       Ophthalmic Systems           6,789     6,242      8.8
                                 --------  --------     ----
    TOTAL                        $407,508  $407,491        -
                                 --------  --------     ----

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems     $149,230  $143,300      4.1
       Diagnostic Systems         138,338   136,188      1.6
                                 --------  --------     ----
    TOTAL                        $287,568  $279,488      2.9
                                 --------  --------     ----

    BD BIOSCIENCES
    --------------
       Cell Analysis             $ 77,379  $ 67,358     14.9
       Discovery Labware           36,372    35,713      1.8
                                 --------  --------     ----
    TOTAL                        $113,751  $103,071     10.4
                                 --------  --------     ----

    TOTAL UNITED STATES          $808,827  $790,050      2.4
                                 --------  --------     ----



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended December 31, (continued)
    (Unaudited; Amounts in thousands)

                                          International
                          ---------------------------------------------
                                                     % Change
                                               ------------------------
                                                           FX      FX
                            2008      2007     Reported  Neutral Impact
                          --------  --------   --------  ------- ------

    BD MEDICAL
    ----------
       Medical Surgical
        Systems           $224,246  $246,066     (8.9)       -   (8.9)
       Diabetes Care        93,780    90,861      3.2      9.3   (6.1)
       Pharmaceutical
        Systems            152,129   151,963      0.1      4.2   (4.1)
       Ophthalmic
        Systems             13,113    12,903      1.6      7.8   (6.2)
                          --------  --------     ----     ----   ----
    TOTAL                 $483,268  $501,793     (3.7)     3.2   (6.9)
                          --------  --------     ----     ----   ----

    BD DIAGNOSTICS
    --------------
       Preanalytical
        Systems           $128,924  $128,169      0.6      8.3   (7.7)
       Diagnostic
        Systems            123,699   115,094      7.5     12.0   (4.5)
                          --------  --------     ----     ----   ----
    TOTAL                 $252,623  $243,263      3.8     10.1   (6.3)
                          --------  --------     ----     ----   ----

    BD BIOSCIENCES
    --------------
       Cell Analysis      $152,142  $137,755     10.4      9.8    0.6
       Discovery
        Labware             36,645    32,906     11.4      8.5    2.9
                          --------  --------     ----     ----   ----
    TOTAL                 $188,787  $170,661     10.6      9.6    1.0
                          --------  --------     ----     ----   ----

    TOTAL INTERNATIONAL   $924,678  $915,717      1.0      6.2   (5.2)
                          --------  --------     ----     ----   ----



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended December 31, (continued)
    (Unaudited; Amounts in thousands)

                                                 Total
                          --------------------------------------------------
                                                            % Change
                                                   -------------------------
                                                               FX       FX
                             2008        2007      Reported  Neutral  Impact
                          ----------  ----------   --------  -------  ------

    BD MEDICAL
    -----------
       Medical Surgical
        Systems           $  480,501  $  498,811     (3.7)     0.7    (4.4)
       Diabetes Care         195,592     189,387      3.3      6.2    (2.9)
       Pharmaceutical
        Systems              194,781     201,941     (3.5)    (0.4)   (3.1)
       Ophthalmic
        Systems               19,902      19,145      4.0      8.1    (4.1)
                          ----------  ----------     ----     ----    ----
    TOTAL                 $  890,776  $  909,284     (2.0)     1.8    (3.8)
                          ----------  ----------     ----     ----    ----

    BD DIAGNOSTICS
    --------------
       Preanalytical
        Systems           $  278,154  $  271,469      2.5      6.1    (3.6)
       Diagnostic
        Systems              262,037     251,282      4.3      6.4    (2.1)
                          ----------  ----------     ----     ----    ----
    TOTAL                 $  540,191  $  522,751      3.3      6.2    (2.9)
                          ----------  ----------     ----     ----    ----

    BD BIOSCIENCES
    --------------
       Cell Analysis      $  229,521  $  205,113     11.9     11.5     0.4
       Discovery
        Labware               73,017      68,619      6.4      5.0     1.4
                          ----------  ----------     ----     ----    ----
    TOTAL                 $  302,538  $  273,732     10.5      9.9     0.6
                          ----------  ----------     ----     ----    ----

    TOTAL REVENUES        $1,733,505  $1,705,767      1.6      4.4    (2.8)
                          ----------  ----------     ----     ----    ----


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , ... May 27, 2016 , ... ... this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and ... the industry, from leading advocates, associations and industry leaders such as Bioness. ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Beleza Medspa ... body fat composition regulations. This is the first time that Coolsculpting is being ... at least every six months to ensure they meet the prescribed body-fat standard, measured ...
(Date:5/27/2016)... ... 2016 , ... Aimed at nurses and employees in the health care world, ... in the nursing and health care industry. It also provides insight to the developing ... , As the nursing industry is coming out of one of the biggest ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... trusted name in the pharmaceutical, medical and food industries. Aside from its GMP ... certification (SIC), providing proof of successfully certified products, services and staff. , Validation ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research ... their dogs straight off the grill. Of the 90 percent of Americans who say ... a hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... instances of hypertension is driving ambulatory blood pressure monitoring ... their elasticity and their ability to respond to different ... This condition can lead to various cardiovascular disorders such ... vascular disease. These diseases are growing in prevalence each ...
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
Breaking Medicine Technology: